{"transactions":[{"id":3315894,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2020-01-09T01:33:14.000Z","date":"2019-10-08","kind":"grant","acquired":true,"shares":500000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Company recently completed a convertible promissory note exchange offer in which Argonne Trading participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the \"Original Note\") beneficially owned by Mr. Klump, the Company (i) issued a new convertible promissory note in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein"}],"balance_after":500000,"derivative":{"exercise_price":0.3,"exercise_date":"2019-10-07","expiration_date":"2024-10-08","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-20-000854","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924320000854/doc4.xml","form_type":"4"}},{"id":3315893,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2020-01-09T01:33:14.000Z","date":"2019-10-08","kind":"grant","acquired":true,"shares":537397,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Company recently completed a convertible promissory note exchange offer in which Argonne Trading participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the \"Original Note\") beneficially owned by Mr. Klump, the Company (i) issued a new convertible promissory note in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein"}],"derivative":{"exercise_price":0.5,"exercise_date":"2019-10-08","expiration_date":"2020-04-01","underlying":"Common Stock","underlying_shares":1075758},"source":{"system":"sec-edgar","filing":"0000899243-20-000854","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924320000854/doc4.xml","form_type":"4"}},{"id":3315892,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2020-01-09T01:33:14.000Z","date":"2019-10-08","kind":"disposition_to_issuer","acquired":false,"shares":500000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Company recently completed a convertible promissory note exchange offer in which Argonne Trading participated, among other non-affiliated investors. Pursuant to the exchange offer, as an inducement to extend the maturity date of a certain convertible promissory note (the \"Original Note\") beneficially owned by Mr. Klump, the Company (i) issued a new convertible promissory note in the principal amount equal to the principal amount of the Original Note plus the accrued but unpaid interest thereon and (ii) issued a warrant to purchase shares of common stock covering fifty percent of the shares of common stock into which the principal amount of the Original Note was convertible."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein"}],"derivative":{"exercise_price":0.5,"exercise_date":"2019-01-08","expiration_date":"2019-10-08","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-20-000854","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924320000854/doc4.xml","form_type":"4"}},{"id":3333308,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-24T00:08:03.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":750000,"derivative":{"exercise_price":0.63,"exercise_date":"2019-12-19","expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000899243-19-030003","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319030003/doc4.xml","form_type":"4"}},{"id":3485444,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-06-20T01:05:21.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments, commencing on September 1, 2019."}],"balance_after":100000,"derivative":{"exercise_price":0.52,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-017515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017515/doc4.xml","form_type":"4"}},{"id":3532933,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2016-04-26","expiration_date":"2021-04-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532932,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":125000,"derivative":{"exercise_price":0.4,"exercise_date":"2016-04-26","expiration_date":"2021-04-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532931,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"disposition_to_issuer","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":0,"derivative":{"exercise_price":1.35,"exercise_date":"2016-04-26","expiration_date":"2021-04-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532930,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":false,"shares":66667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Klump Children's Gift Trust"},"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532929,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":66667,"ownership":{"direct":false,"nature":"By the Klump Children's Gift Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":66667,"derivative":{"exercise_price":0.4,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532928,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"disposition_to_issuer","acquired":false,"shares":66667,"ownership":{"direct":false,"nature":"By the Klump Children's Gift Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532927,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.3,"exercise_date":"2019-01-08","expiration_date":"2024-01-08","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532926,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":false,"shares":1933333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":1933333},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532925,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":1933333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":1933333,"derivative":{"exercise_price":0.4,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":1933333},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532924,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1933333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":1933333},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532923,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2018-02-16","expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532922,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":1000000,"derivative":{"exercise_price":0.4,"exercise_date":"2018-02-16","expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532921,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-02-16","expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532920,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":62500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":187500,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532919,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":33333,"ownership":{"direct":false,"nature":"By the Klump Children's Gift Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532918,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"grant","acquired":true,"shares":1716666,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":12184519,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532917,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":true,"shares":125000,"price":0.4,"value":50000.0,"ownership":{"direct":true},"balance_after":125000,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532916,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":true,"shares":66667,"price":0.4,"value":26666.8,"ownership":{"direct":false,"nature":"By the Klump Children's Gift Trust"},"balance_after":66667,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532915,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":true,"shares":500000,"price":0.3,"value":150000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":10467853,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532914,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":true,"shares":1933333,"price":0.4,"value":773333.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":9967853,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3532913,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-10T21:25:57.000Z","date":"2019-05-08","kind":"exercise","acquired":true,"shares":1000000,"price":0.4,"value":400000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of CytoDyn Inc. (the \"Company\") are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":8034520,"source":{"system":"sec-edgar","filing":"0000899243-19-013098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319013098/doc4.xml","form_type":"4"}},{"id":3698693,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2019-01-10T22:27:18.000Z","date":"2019-01-08","kind":"purchase","acquired":true,"shares":500000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $500,000 (i) a $500,000 convertible promissory note, bearing interest at 10.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.50 per share and matures on October 8, 2019, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note with an exercise price of $0.30 per share and an expiration date of January 8, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held by Argonne Trading LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":500000,"derivative":{"exercise_price":0.3,"exercise_date":"2019-01-08","expiration_date":"2024-01-08","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-19-000989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319000989/doc4.xml","form_type":"4"}},{"id":3698692,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2019-01-10T22:27:18.000Z","date":"2019-01-08","kind":"purchase","acquired":true,"shares":500000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $500,000 (i) a $500,000 convertible promissory note, bearing interest at 10.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.50 per share and matures on October 8, 2019, and (ii) a warrant covering 50% of the number of shares underlying the convertible promissory note with an exercise price of $0.30 per share and an expiration date of January 8, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Does not include additional shares issuable upon conversion of accrued interest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are held by Argonne Trading LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":500000,"derivative":{"exercise_price":0.5,"exercise_date":"2019-01-08","expiration_date":"2019-10-08","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-19-000989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319000989/doc4.xml","form_type":"4"}},{"id":3760337,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:17.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":66667,"ownership":{"direct":false,"nature":"By the Klump Children's Gift Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":66667,"derivative":{"exercise_price":1,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-18-029256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029256/doc4.xml","form_type":"4"}},{"id":3760336,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:17.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":1933333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":1933333,"derivative":{"exercise_price":1,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":1933333},"source":{"system":"sec-edgar","filing":"0000899243-18-029256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029256/doc4.xml","form_type":"4"}},{"id":3760335,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:17.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":1000000,"derivative":{"exercise_price":0.75,"exercise_date":"2018-02-16","expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-029256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029256/doc4.xml","form_type":"4"}},{"id":3760334,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:01:17.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":125000,"derivative":{"exercise_price":1.35,"exercise_date":"2016-04-26","expiration_date":"2021-04-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-18-029256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029256/doc4.xml","form_type":"4"}},{"id":3760333,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:01:17.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":80822,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options (including predecessor options) vested with respect to 5,822 shares on September 1, 2018, and the remaining shares vest in three equal quarterly installments commencing on December 1, 2018."}],"balance_after":80822,"derivative":{"exercise_price":0.47,"expiration_date":"2028-08-10","underlying":"Common Stock","underlying_shares":80822},"source":{"system":"sec-edgar","filing":"0000899243-18-029256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029256/doc4.xml","form_type":"4"}},{"id":3760332,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:01:17.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":7034520,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":7034520,"source":{"system":"sec-edgar","filing":"0000899243-18-029256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029256/doc4.xml","form_type":"4"}},{"id":3762686,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:32:06.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":66667,"ownership":{"direct":false,"nature":"By the Klump Children's Gift Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0000899243-18-029191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029191/doc4.xml","form_type":"4"}},{"id":3762685,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:32:06.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1933333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2016-12-12","expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":1933333},"source":{"system":"sec-edgar","filing":"0000899243-18-029191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029191/doc4.xml","form_type":"4"}},{"id":3762684,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:32:06.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2018-02-16","expiration_date":"2023-02-16","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000899243-18-029191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029191/doc4.xml","form_type":"4"}},{"id":3762683,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:32:06.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.35,"exercise_date":"2016-04-26","expiration_date":"2021-04-26","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-18-029191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029191/doc4.xml","form_type":"4"}},{"id":3762682,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:32:06.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":80822,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested with respect to 5,822 shares on September 1, 2018, and the remaining shares vest in three equal quarterly installments commencing on December 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.47,"expiration_date":"2028-08-10","underlying":"Common Stock","underlying_shares":80822},"source":{"system":"sec-edgar","filing":"0000899243-18-029191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029191/doc4.xml","form_type":"4"}},{"id":3762681,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:32:06.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":7034520,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held by Argonne Trading, LLC, a Georgia limited liability company (\"Argonne Trading\"). Argonne Capital Group, LLC, a Georgia limited liability company (\"Argonne Capital\"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029191/doc4.xml","form_type":"4"}},{"id":3845701,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":152485,"kind":"person","name":"Klump Michael A","position":1,"cik":"0001748882","reported_name":"Klump Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-08-14T21:32:10.000Z","date":"2018-08-10","kind":"grant","acquired":true,"shares":80822,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest commencing on September 1, 2018 with respect to 5,822 shares, and will vest in three equal quarterly installments commencing on December 1, 2018 with respect to the remaining shares."}],"balance_after":80822,"derivative":{"exercise_price":0.47,"expiration_date":"2028-08-10","underlying":"Common Stock","underlying_shares":80822},"source":{"system":"sec-edgar","filing":"0000899243-18-022326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318022326/doc4.xml","form_type":"4"}}]}